Provectus Provides Update on GI Tumor Program for Investigational Cancer Drug PV-10
08 juil. 2019 08h00 HE
|
Provectus Biopharmaceuticals Inc.
Metastatic neuroendocrine tumors: Monotherapy data presentations planned. Phase 2 combination therapy trial designs with different classes of checkpoint inhibitor drugs being developed.Metastatic...